Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
3.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
4.
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
Cancer
; 128(10): 1996-2004, 2022 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35167125
5.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111391
6.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671975
7.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
8.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
9.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 97(5): 562-573, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132679
10.
Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
J Oncol Pharm Pract
; 28(2): 421-424, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33611974
11.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738
12.
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Am J Hematol
; 96(12): 1595-1603, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34559902
13.
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Haematologica
; 105(2): 468-477, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221782
14.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119237
15.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943323
16.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Am J Hematol
; 94(11): 1244-1253, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456261
17.
Evaluating the adverse effects of melphalan formulations.
J Oncol Pharm Pract
; 25(7): 1631-1637, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30336728
18.
The proteasome and proteasome inhibitors in multiple myeloma.
Cancer Metastasis Rev
; 36(4): 561-584, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196868
19.
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Br J Haematol
; 181(4): 433-446, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748955
20.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Br J Haematol
; 180(2): 271-275, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048105